Lacktman Comments on New Connecticut Law Allowing Telemedicine Prescriptions
June 27, 2018
mHealthIntelligence
Partner Nate Lacktman was quoted in an mHealthIntelligence article, “New Connecticut Law Enables Providers to Prescribe Via Telemedicine,” about the passage of a law that allows health care providers to use telemedicine to prescribe certain controlled substances for mental health and substance abuse treatment.
Lacktman said the new law is a “huge benefit” for Connecticut patients with mental health or substance abuse issues, and “follows a growing trend among states to amend and eliminate prior statutory prohibitions on telemedicine prescribing of controlled substances, particularly in light of the goal of supporting the availability of alternative therapies to address the opioid crisis.”
Lacktman said the new law is a “huge benefit” for Connecticut patients with mental health or substance abuse issues, and “follows a growing trend among states to amend and eliminate prior statutory prohibitions on telemedicine prescribing of controlled substances, particularly in light of the goal of supporting the availability of alternative therapies to address the opioid crisis.”
People
Related News
March 13, 2026
In the News
Chris Babcock and Chris Converse on Wave of Companies Moving to Texas
Foley & Lardner LLP partners Chrisopher Babcock and Chris Converse commented on the widening trend of companies reincorporating to Texas in the Houston Business Journal article, “Texas law changes could spark wave of corporate redomestication proposals."
March 12, 2026
In the News
Louis Lehot Explores M&A's Growing Blitzhire Phenomenon
Foley & Lardner LLP partner Louis Lehot authors article on the emergence of blitzhires in the Mergers & Acquisitions article, “Blitzhires: The New Fast-Moving M&A Deal.”
March 10, 2026
In the News
Aaron Maguregui Shares Insights on Shadow AI Risks in Health Care
Foley & Lardner LLP partner Aaron Maguregui was quoted in the Part B News article, “Do you need AI policy? Experts suggest guardrails as 'shadow AI' spreads,” discussing the emerging risks of unsanctioned 'shadow AI' use by clinicians and the need to establish robust AI governance.